Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial.

导出 OA

翻译打印收藏纠错

作者： Doris Patricia,Molina-Henry ^[1] ; Rema,Raman ^[1] ; Andy,Liu ^[1] ; Oliver,Langford ^[1] ; Keith,Johnson ^[2] ; Leona K,Shum ^[1] ; Crystal M,Glover ^[3] ; Shobha,Dhadda ^[4] ; Michael,Irizarry ^[4] ; Gustavo,Jimenez-Maggiora ^[1] ; Joel B,Braunstein ^[5] ; Kevin,Yarasheski ^[5] ; Venky,Venkatesh ^[5] ; Tim,West ^[5] ; Philip B,Verghese ^[5] ; Robert A,Rissman ^[6] ; Paul,Aisen ^[1] ; Joshua D,Grill ^[7] ; Reisa A,Sperling ^[2]

作者单位： Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego, California, USA. ^[1] Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.;Brigham and Women's Hospital, Boston, Massachusetts, USA. ^[2] Rush Alzheimer's Disease Center, Chicago, Illinois, USA.;Department of Psychiatry and Behavioral Sciences, Rush University Medical College, Chicago, Illinois, USA.;Department of Neurological Sciences, Rush Medical College, Chicago, Illinois, USA. ^[3] Eisai Inc., Nutley, New Jersey, USA. ^[4] C2N Diagnostics, St. Louis, Missouri, USA. ^[5] Department of Physiology and Neuroscience, Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego, California, USA. ^[6] Institute for Memory Impairments and Neurological Disorders, University of California Irvine, Irvine, California, USA. ^[7]

关键词 amyloid biomarker ethnicity plasma positron emission tomography race